US FDA panel gives nod to Vivus obesity drug
WASHINGTON Feb 22 (Reuters) - An experimental obesity drug from Vivus Inc won a U.S. panel's support on Wednesday, raising hopes regulators would approve a weight-loss pill for the first time in 13 years.
A panel of outside experts to the Food and Drug Administration voted 20-2 to recommend approval of Qnexa, meant to treat obesity and its accompanying health problems.
The FDA usually follows panel recommendations, although it is not required to, and a final decision is expected by April 17.
- U.S. nurse defies Maine's Ebola quarantine, takes bike ride |
- Clashes erupt as Israeli police kill Palestinian suspected of shooting Jewish far-rightist
- Apple's Cook: 'I'm proud to be gay'
- SoftBank's humanoid robot lands job as Nescafe salesman
- Ukraine, Russia, EU likely to agree gas supply deal Thursday: officials